Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
27/08/26	SEK 13.25	-2.93%
26/08/26	SEK 13.65	+0.37%
25/08/26	SEK 13.60	+3.03%
24/08/26	SEK 13.20	0.00%
21/08/26	SEK 13.20	+3.12%

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 12:56:14 27/08/2026 +04			5-day change	1st Jan Change
13.25 ^SEK	-2.93%		-0.38%	-33.08%

08-21	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate	MT

Market Cap	96.36M 10.11M 8.67M 8.14M 7.44M 14.03M 964M 14.1M 37.34M 486M 37.95M 37.12M 1.61B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	96.36M 10.11M 8.67M 8.14M 7.44M 14.03M 964M 14.1M 37.34M 486M 37.95M 37.12M 1.61B	EV / Sales 2026 *	2.08x	EV / Sales 2027 *	2.91x
Free-Float	44.46%	Yield 2026 *	-	Yield 2027 *	-

08-21	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate	MT
08-20	Annexin Pharmaceuticals AB Receives The International Nonproprietary Name Vanexin For The Drug Candidate ANXV	CI
07-21	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
07-16	Calendar, Thursday, July 16	FW
06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW
06-09	Calendar Wednesday June 10	FW
05-21	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo	CI
05-11	Annexin receives German approval for ANXV clinical trial	RE
05-11	Annexin Pharmaceuticals AB Receives Clinical Trial Approval for ANXV in Germany, Widening Patient Recruitment in the Nexus Study	CI
04-23	Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

08-21	Annexin advances the NEXUS study to include patients who received an anti-VEGF injection	AQ
08-20	Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV	AQ
07-21	Annexin updates on nine patients treated in NEXUS study	AQ
07-03	Annexin's rights issue 98 percent subscribed	AQ
06-23	Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO	AQ

Annexin Pharmaceuticals AB Stock

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation : Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news : Annexin Pharmaceuticals AB

Press Releases : Annexin Pharmaceuticals AB

News in other languages : Annexin Pharmaceuticals AB

Quotes and Performance

Price Extremes

Managers and Directors : Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

1 day	-2.93%
1 week	-0.38%
Current month	+8.16%
1 month	+7.29%
6 months	-16.67%
Current year	-33.08%

1 week	12.6	14
1 month	11.45	14
Current year	11.05	23.6
1 year	11.05	29.8
3 years	11.05	97.6
5 years	11.05	225
10 years	11.05	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	01/01/2019
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	01/01/2016
Susanne Andersson DFI	Director of Finance/CFO	55	11/04/2023

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	01/01/2017
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	01/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	-2.93%	-0.38%	-50.19%	-82.33%	10.11M
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	70.42B
ARGENX SE	+1.20%	+2.71%	+49.64%	+93.61%	65.4B
BIONTECH SE	-1.31%	-0.50%	+7.41%	-4.29%	28.28B
WUXI BIOLOGICS (CAYMAN) INC.	-0.49%	+1.73%	+59.01%	+11.60%	26.57B
INSMED INCORPORATED	+0.40%	-4.80%	-5.89%	+469.55%	27.16B
GENMAB A/S	+1.53%	+1.96%	+37.56%	-17.00%	20.09B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	20.61B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.77%	-1.59%	+13.19%	+543.56%	15.87B
EXELIXIS, INC.	-1.09%	+3.14%	+46.32%	+155.12%	13.9B
Average	+0.25%	+1.31%	+48.75%	+169.38%	28.83B
Weighted average by Cap.	+1.13%	+0.72%	+56.61%	+157.70%

	2026 *	2027 *
Net sales	46.3M 4.86M 4.17M 3.91M 3.57M 6.74M 463M 6.78M 17.94M 234M 18.23M 17.84M 774M	33.1M 3.47M 2.98M 2.8M 2.55M 4.82M 331M 4.84M 12.83M 167M 13.04M 12.75M 553M
Net income	-11.5M -1.21M -1.04M -972K -888K -1.67M -115M -1.68M -4.46M -58.04M -4.53M -4.43M -192M	-24.9M -2.61M -2.24M -2.1M -1.92M -3.63M -249M -3.64M -9.65M -126M -9.81M -9.59M -416M
Net Debt	-	-